Equities

Inhalation Sciences Sweden AB

ISAB:AKT

Inhalation Sciences Sweden AB

Actions
  • Price (SEK)1.81
  • Today's Change0.085 / 4.93%
  • Shares traded300.00
  • 1 Year change-54.52%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Inhalation Sciences Sweden AB is a Sweden-based company, which develops and sells labtech equipment for inhalation research. The Company’s primary product is PreciseInhale, which is a laboratory system that lets scientists measure how inhaled particles act in lungs and affect human health. PreciseInhale is a dry powder aerosol research and development system, which generate aerosols and data of a quality. The system helps to eliminate poor candidate drugs before clinical trials. The secondary product is LaminarPace, a tool for drying small amounts of drug substance. The Company’s customers comprise Dow Chemical Group, Kings College London and Karolinska Institutet, among others. The Company’s main shareholder is Nordnet Pensionsforsakring.

  • Revenue in SEK (TTM)15.48m
  • Net income in SEK-3.93m
  • Incorporated2004
  • Employees8.00
  • Location
    Inhalation Sciences Sweden ABHalsovagen 7, Novum Floor 6, Elevator EHUDDINGE 141 57SwedenSWE
  • Phone+46 85 468845846
  • Websitehttps://www.inhalation.se/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Invent Medic Sweden AB6.73m-8.04m13.44m9.00--3.44--2.00-0.1939-0.19390.16130.05660.60842.314.34841,046.30-72.67-97.56-133.97-121.0677.4377.16-119.45-490.980.3951-12.430.2703--115.97177.5328.77---22.61--
VibroSense Dynamics AB2.02m-7.28m14.35m----1.24--7.12-0.3547-0.35470.09280.45150.16257.736.49---58.69-49.44-70.14-56.99-193.04-242.79-361.21-466.016.73--0.00--17.5029.39-3.18--32.90--
Miris Holding AB (publ)17.32m-9.41m18.04m10.00--4.40--1.04-0.2092-0.20920.36410.02710.8240.11177.251,732,100.00-44.74-59.61-95.35-111.0897.8386.68-54.30-103.610.7091-8.080.0903---17.192.53-20.86------
Level Bio AB (publ)24.17m-10.77m18.39m11.00--3.58--0.7608-0.1688-0.16880.37380.0811.325.585.131,858,971.00-58.81-6.39-100.69-10.51-3.92---44.55-4.090.8205-145.540.00---23.107.83-326.08---4.64--
Perpetua Medical AB (publ)6.32m-8.48m21.70m0.00--2.10--3.44-3.06-3.061.912.280.407416.136.19---54.70-83.52-74.20-102.19-65.03-70.52-134.27-250.306.39--0.00---1.7657.204.63--8.89--
Chordate Medical Holding AB (publ)1.12m-27.82m23.33m3.00--1.13--20.77-41.97-41.971.6721.160.0363-0.7463.53374,390.00-90.02-91.98-110.15-122.85219.20209.52-2,477.25-3,295.752.34--0.00--799.630.6511-4.45------
Codelab Capital AS-98.44bn-98.44bn23.42m29.00--0.1505----------0.4624-----------6.63---7.43--83.80---39.82----0.00---69.66-3.83119.43---12.19--
Inhalation Sciences Sweden AB15.48m-3.93m26.16m8.00--2.33--1.69-0.2796-0.27961.090.74090.80960.63284.371,935,000.00-20.53-27.93-29.23-43.8286.2971.13-25.36-48.022.81-6.490.0639--43.5526.3360.87------
Bio Vitos Pharma AB1.11m-14.84m26.87m1.00--0.7539--24.23-1.50-1.500.05970.90460.04570.0923.021,108,910.00-61.08-31.11-62.90-32.9290.59---1,338.03-1,026.765.84--0.00--126.97--13.64------
BBS-Bioactive Bone Substitutes Oyj0.00-41.16m30.71m----0.5665-----0.2069-0.20690.000.17650.00-------35.38-25.12-45.41-28.54-----------27.510.5953-------12.64------
ProstaLund AB17.57m-21.64m32.97m6.00--0.4738--1.88-0.2752-0.27520.22260.56560.26270.330812.78---32.35-29.14-39.54-35.0172.7375.26-123.16-68.940.7618-155.800.1065--27.5410.36-53.27--20.35--
Scandinavian ChemoTech AB5.03m-15.70m37.74m5.00--4.53--7.50-0.8655-0.86550.26470.3840.31620.59471.37838,666.70-98.64-87.29-98.64-118.5529.67252.05-311.96-2,122.77---22.930.00--496.6219.137.28------
Scandinavian Real Heart AB0.00-75.02m38.88m12.00--0.4249-----0.5182-0.51820.000.44250.00----0.00-73.46-24.27-87.03-26.81--832.41---6,070.11---700.380.1023---100.00---385.97---25.76--
Data as of Nov 12 2024. Currency figures normalised to Inhalation Sciences Sweden AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.